Heron Therapeutics (HRTX) Accumulated Depreciation & Amortization: 2011-2024
- Heron Therapeutics' Accumulated Depreciation & Amortization rose 4.81% to $17.8 million in Q4 2024 from the same period last year, while for Dec 2024 it was $62.4 million, marking a year-over-year increase of 12.58%. This contributed to the annual value of $17.8 million for FY2024, which is 4.81% up from last year.
- Heron Therapeutics' Accumulated Depreciation & Amortization amounted to $17.8 million in Q4 2024, which was up 4.81% from $17.0 million recorded in Q4 2023.
- In the past 5 years, Heron Therapeutics' Accumulated Depreciation & Amortization ranged from a high of $17.8 million in Q4 2024 and a low of $10.9 million during Q4 2020.
- Its 3-year average for Accumulated Depreciation & Amortization is $16.4 million, with a median of $17.0 million in 2023.
- Data for Heron Therapeutics' Accumulated Depreciation & Amortization shows a peak YoY soared of 35.48% (in 2020) over the last 5 years.
- Quarterly analysis of 5 years shows Heron Therapeutics' Accumulated Depreciation & Amortization stood at $10.9 million in 2020, then increased by 21.81% to $13.2 million in 2021, then rose by 7.93% to $14.3 million in 2022, then increased by 19.14% to $17.0 million in 2023, then grew by 4.81% to $17.8 million in 2024.
- Its last three reported values are $17.8 million in Q4 2024, $17.0 million for Q4 2023, and $14.3 million during Q4 2022.
